Protara Therapeutics (NASDAQ: TARA) will present updated interim data from its Phase 2 ADVANCED‑2 trial of TARA‑002 at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco on February 27, 2026. The presentation will focus on safety and efficacy outcomes from approximately 25 six‑month evaluable BCG‑unresponsive non‑muscle invasive bladder cancer (NMIBC) patients, as well as interim safety data from both BCG‑naïve and BCG‑unresponsive cohorts.
Prior to this announcement, Protara reported a 100 % six‑month landmark complete response rate in the BCG‑unresponsive cohort on December 5, 2024, and a positive update on BCG‑naïve patients on December 3, 2025. These earlier results set the stage for the current data, which will provide a more comprehensive view of TARA‑002’s activity across both patient populations and help determine the next steps toward regulatory submission.
The NMIBC market represents a significant opportunity: roughly 80 % of bladder cancer diagnoses are non‑muscle invasive, with about 65,000 new cases annually in the United States alone. Protara estimates the addressable market for TARA‑002 could exceed $1 billion, positioning the therapy to address a substantial unmet need in a field with limited approved options and supply constraints for standard BCG therapy.
CEO Jesse Shefferman emphasized the importance of the upcoming data, stating, “These interim results will confirm the durability and safety profile of TARA‑002 in BCG‑unresponsive patients and bring us closer to a regulatory submission that could transform the NMIBC treatment landscape.” He added that the company remains on track to provide a full update on the BCG‑unresponsive cohort later in the year.
Financially, Protara had $145.6 million in cash, cash equivalents, and investments as of June 30, 2025, and closed a $75 million public offering on December 8, 2025. The company expects the current cash position to fund operations into mid‑2027, giving it sufficient runway to advance TARA‑002 through the remaining clinical milestones and potential commercialization.
Strategically, the presentation is a key inflection point. Positive data will support the company’s plan to file a regulatory submission for TARA‑002 in BCG‑unresponsive NMIBC, leveraging its Breakthrough and Fast Track designations. Successful outcomes could accelerate market entry and unlock the projected $1 billion+ addressable revenue, while also reinforcing Protara’s broader pipeline, including its lymphatic malformation program and IV choline chloride development.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.